A variant of the IL7 gene predicts the toxicity of checkpoint inhibitors in patients with cancer, via a mechanism shared with autoimmune diseases — which could inform biomarker and treatment strategies in both of these contexts.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint inhibitor therapy in melanoma patients: a retrospective cohort study
BMC Cancer Open Access 28 March 2025
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout

References
Boutros, C. et al. Nat. Rev. Clin. Oncol. 13, 473–486 (2016).
Postow, M. A., Sidlow, R. & Hellmann, M. D. N. Engl. J. Med. 378, 158–168 (2018).
Hua, C. et al. JAMA Dermatol. 152, 45–51 (2016).
Groha, S. Nat. Med. https://doi.org/10.1038/s41591-022-02094-6 (2022).
Taylor, C. A. Nat. Med. https://doi.org/10.1038/s41591-022-02095-5 (2022).
Barata, J. T., Durum, S. K. & Seddon, B. Nat. Immunol. 20, 1584–1593 (2019).
Dooms, H. J. Autoimmun. 45, 40–48 (2013).
Rivière, E. et al. Arthritis Rheumatol. 73, 631–640 (2021).
Pachynski, R. K. et al. J. Immunother. Cancer 9, e002903 (2021).
Murakami, S. & Jaffrey, S. R. Mol. Cell 82, 2236–2251 (2022).
Childs-Disney, J. L. et al. Nat. Rev. Drug Discov. 21, 736–762 (2022).
Stanley, R. F. & Abdel-Wahab, O. Nat. Cancer 3, 536–546 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.R. is an occasional consultant for Roche, BMS, MSD, Sanofi, AstraZeneca, Pierre Fabre, Novartis and scientific co-Founder of Ribonexus; S.V. is scientific co-founder of Ribonexus Xavier Mariette is an occasional consultant for AstraZeneca, Novartis, BMS, Galapagos, Pfizer, GSK.
Rights and permissions
About this article
Cite this article
Robert, C., Vagner, S. & Mariette, X. Using genetics to predict toxicity of cancer immunotherapy. Nat Med 28, 2471–2472 (2022). https://doi.org/10.1038/s41591-022-02096-4
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-022-02096-4